In May 2024, On Tuesday, Pliant Therapeutics announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patients ...
Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback